<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04309916</url>
  </required_header>
  <id_info>
    <org_study_id>KCAB_002</org_study_id>
    <nct_id>NCT04309916</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy and Safety of Tegoprazan in ERD Patients With Nighttime Heartburn and Sleep Disturbance</brief_title>
  <official_title>A Multicenter, Double-blind, Randomized, Active-controlled Phase 4 (Pilot) Study to Evaluate the Efficacy and Safety of Tegoprazan in ERD Patients With Nighttime Heartburn and Sleep Disturbance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HK inno.N Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HK inno.N Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to compare the nighttime heartburn and sleep disturbance improvement effect
      of Tegoprazan 50mg and Eomeprazole 40mg in patients with ERD patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center, double-blind, randomized, active-controlled phase 4 (pilot) study.
      Subjects will be randomly assigned to one of the two treatment groups (tegoprazan 50mg,
      esomeprazole 40mg)
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to first nighttime heartburn-free interval (days))</measure>
    <time_frame>2 week</time_frame>
    <description>Number of days to reach the without symptoms of nighttime heartburnafter the start of drug administration for clinical trials.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of days without nighttime heartburn during the 2-week dosing period</measure>
    <time_frame>2 week</time_frame>
    <description>Percentage of days without nighttime heartburn = Number of days without nighttime heartburn symptoms during the dosing period / Number of days when nighttime heartburn was assessed x 100</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Erosive Reflux Disease</condition>
  <arm_group>
    <arm_group_label>Tegoprazan 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tegoprazan 50mg tablet, once daily, oral administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Esomeprazole 40mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Esomeprazole 40mg tablet, once daily, oral administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tegoprazan</intervention_name>
    <description>Tegoprazan 50mg tablet</description>
    <arm_group_label>Tegoprazan 50mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <description>Esomeprazole 40mg tablet</description>
    <arm_group_label>Esomeprazole 40mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects aged between 19 and 75 years

          2. Subjects who have erosive reflux disease

        Exclusion Criteria:

          1. Unable to undergo upper GI endoscopy

          2. Symptoms of primary or secondary esophageal movement disorders

          3. Planning or Perform surgery that can affect gastric acid secretion (e.g., upper
             gastrectomy, Vagotomy, etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang Kil Lee, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ah Rong Kim</last_name>
    <phone>82-2-6477-0266</phone>
    <email>ahrong.kim@kolmar.co.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Eun Ji Kim</last_name>
    <phone>82-2-6477-0270</phone>
    <email>eunji.kim@kolmar.co.kr</email>
  </overall_contact_backup>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 13, 2020</study_first_submitted>
  <study_first_submitted_qc>March 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2020</study_first_posted>
  <last_update_submitted>March 13, 2020</last_update_submitted>
  <last_update_submitted_qc>March 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyssomnias</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
    <mesh_term>Heartburn</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

